In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Initiating angiotensin receptor blockade and neprilysin inhibitor (ARNI) in acute heart failure with mechanical support

Session Poster Session 6

Speaker Assistant Professor Ho-Tsung Hsin

Event : ESC Congress 2019

  • Topic : heart failure
  • Sub-topic : Acute Heart Failure: Pharmacotherapy
  • Session type : Poster Session

Authors : HT Hsin (Taipei County,TW), KM Chiu (Taipei County,TW)

H.T. Hsin1 , K.M. Chiu2 , 1Cardiovascular Intensive Care Unit, Far-Eastern Memorial Hospital - Taipei County - Taiwan , 2Division of Cardiovascular Surgery, Cardiovasular Center, FEMH - Taipei County - Taiwan ,

European Heart Journal ( 2019 ) 40 ( Supplement ), 3294

Introduction: Heart failure still poses great threat to the afflicted patients and enormous burden to our health-care community. Thanks to the ushering of “Angiotensin Receptor Blockade and Neprilysin Inhibitor (ARNI), Entresto®”, we have made further progress by saving one out of 5 of our patients with chronic heart failure in this decade. Current treatment guidelines have suggested the commencement of ARNI in patients with chronic stable heart failure. There is no mention of starting ARNI in the very beginning of the acute phase of heart failure, especially in the patients needing mechanical support. We try to illustrate the clinical picture and implication of ARNI in acute heart failure.

Method: The study was conducted in a 20-bed based cardiovascular intensive care unit of a tertiary-referring center of Taiwan. We enrolled patients of cardiogenic shock, who were put on left ventricular assist device (LVAD) (CentriMag). Those who were dependent on any vasopressors (eg. nor-adrenaline or vasopressin) were excluded. Concurrent usage of inotropes, such as adrenalin, dopamine or dobutamine, would not preclude our application of ARNI and enrollment. The endpoint of this study were: successful weaning of LVAD, cardiovascular death, and the percentage of achieving guideline-suggested target dose of ARNI.

Results: From Jan. 2017 to Jan. 2019., there were 30 patients put on LVAD with CentriMag. Thirteen patients were excluded as their hemodynamics depended on nor-adrenaline. Seventeen patients of 53.1±9.6-year-old were enrolled and 13 of them were successfully rid of LVAD. Four patients succumbed during the support of LVAD, and 3 of them were due to cardiovascular death. Upon enrollment the LVEF was 18±10.1% and NT pro-BNP was 10327±12629 pg/ml. Fifty-three percent of the enrollee could be prescribed with the target dose of 200mg bid Entresto® within 5.1±3.6 days of initiating ARNI, but only 23.5% could tolerate 200mg bid as maintenance. On initiating ARNI, on-going acute kidney injury were taking place in 76.5% of our enrollee, but only 23.5% suffered persistent renal failure, depending on long-term renal replacement therapy. After 27.8±23.0 days of LVAD, the LVEF improved (43.3±23.0%) sufficing the weaning off.

Conclusion: The very beginning of acute heart failure may have the highest surge of neurohormonal bombardment by renin-agiotensin-aldosterone system. Initiating ARNI in this stage, particularly in patients needing mechanical support, may offer some clinical benefit, regardless of initial renal function.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are